Trial Profile
Impact of Humira Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis; Uveitis
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors AbbVie
- 18 Feb 2020 Status changed from active, no longer recruiting to completed.
- 06 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 22 May 2018 Planned End Date changed from 2 May 2019 to 31 Dec 2019.